World Federation of Neurology Launches Global Brain Health Awareness Campaign
USA - English
News provided by
Share this article
Share this article
LONDON, Feb. 12, 2021 /PRNewswire/ The World Federation of Neurology is pleased to announce its launch of the Brain Health Initiative, a global campaign to promote the importance of brain health. This initiative centers upon free, comprehensive information on a variety of topics such as why brain health is important and what happens when brains are not healthy. The programming aims to reduce the burden of brain diseases and disorders, which are the second leading cause of death globally.
Prothena Corporation plc: Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update
VITAL study 9-month results expected to be presented at medical conference in 2021
Prasinezumab
New pre-specified exploratory subgroup analyses from Part 1 of the Phase 2 PASADENA study to be presented at the 15th International Conference for Alzheimer s and Parkinson s Diseases in March 2021 (ADPD 2021)
$60 million clinical milestone payment to be achieved upon first patient dosed in late-stage Phase 2b study in patients with early Parkinson s disease; further details expected in 2Q 2021
Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference
COVID-19 vaccine should be recommended to patients with Parkinson’s disease, experts say
Patients with Parkinson s disease (PD) and healthcare professionals caring for them have expressed concerns about the COVID-19 vaccine s efficacy and safety in the specific context of PD and its symptomatic treatment. In a commentary just published in the
Journal of Parkinson s Disease, a set of experts addresses these concerns from an evidence-based perspective. Their conclusion is that COVID-19 vaccination with approved vaccines should be recommended to persons with PD, unless there is a specific contraindication. The arrival of these vaccines has created hope for people with PD, as this can help to mitigate their risk of becoming infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which can lead to serious, life-threatening disease, at least among those with more advanced PD, explains lead author Bastiaan R. Bloem, MD, PhD, Radboud University Nijmegen Medica
E-Mail
Amsterdam, NL, February 3, 2021 - Patients with Parkinson s disease (PD) and healthcare professionals caring for them have expressed concerns about the COVID-19 vaccine s efficacy and safety in the specific context of PD and its symptomatic treatment. In a commentary just published in the
Journal of Parkinson s Disease, a set of experts addresses these concerns from an evidence-based perspective. Their conclusion is that COVID-19 vaccination with approved vaccines should be recommended to persons with PD, unless there is a specific contraindication. The arrival of these vaccines has created hope for people with PD, as this can help to mitigate their risk of becoming infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which can lead to serious, life-threatening disease, at least among those with more advanced PD, explains lead author Bastiaan R. Bloem, MD, PhD, Radboud University Nijmegen Medical Center; Donders Institute for Brain, Cognitio
Press release content from Business Wire. The AP news staff was not involved in its creation.
Biorasi Welcomes Neurology Professor Dr. Ole Isacson to Scientific Advisory Board
January 26, 2021 GMT
MIAMI (BUSINESS WIRE) Jan 26, 2021
Biorasi, a leading global full-service contract research organization (CRO), is proud to announce the appointment of Ole Isacson, MD, PhD, Professor of Neurology and Neuroscience, to the position of Scientific Advisory Board (SAB) member. In this role, Dr. Isacson will provide leadership and clinical expertise for neurology clinical trials and related areas at Biorasi.
ADVERTISEMENT
“I look forward to working with Dr. Isacson in expanding our knowledge base in neurology, including rare and urgent diseases,” said Jimmy El Hokayem, PhD, Head of the Neurology and Regenerative Medicine Center of Excellence and Associate Director of Program Development at Biorasi. “I genuinely believe that his unique profile as one of today’s prominent clinical l